Association of complement components with risk of colorectal cancer: A systematic review and meta-analysis

Table 1 Meta-analysis of complement component proteins and clinicopathological features of colorectal cancer patients

Clinicopathological feature	Reference	No. of studies	Model	Pooled RR (95%CI)	P value	Heterogeneity
						I2 (%)	P value
CD55
Age (> 60 years old)	High vs low expression	2	Fixed	1.16 (0.92-1.45)	0.21	0	0.58
Sex (male)	High vs low expression	3	Fixed	1.09 (0.90-1.33)	0.36	0	0.51
Lymph node metastasis	High vs low expression	3	Fixed	1.30 (1.03-1.63)	0.03	0	0.70
Differentiation	High vs low expression	3	Fixed	1.09 (0.93-1.29)	0.28	0	0.95
T3 + T4	High vs low expression	3	Fixed	1.11 (0.99-1.24)	0.08	0	0.95
M1	High vs low expression	3	Random	1.52 (0.43-5.43)	0.52	86	< 0.001
CD59
Age (> 60 years old)	High vs low expression	2	Fixed	0.88 (0.66-1.15)	0.34	0	0.66
Sex (male)	High vs low expression	2	Fixed	0.85 (0.68-1.06)	0.14	0	0.81
Lymph node metastasis	High vs low expression	2	Fixed	1.53 (1.12-2.08)	0.007	53	0.14
CD46
Age (> 60 years old)	High vs low expression	2	Fixed	1.15 (0.86-1.52)	0.35	0	0.98
Sex (male)	High vs low expression	2	Fixed	0.87 (0.68-1.10)	0.24	0	0.63
Lymph node metastasis	High vs low expression	2	Random	0.81 (0.39-1.66)	0.56	83	0.01
Differentiation	High vs low expression	2	Fixed	1.30 (1.04-1.63)	0.02	0	0.69
T3 + T4	High vs low expression	2	Random	0.75 (0.35-1.60)	0.46	80	0.03

RR: Risk ratio; CI: Confidence interval; CD: Cluster of differentiation.